Clinical Trial Update: Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma [Phase 4]

View source ↗

Summary

Phase 4 study evaluating safety, tolerability, and efficacy of Kyprolis (carfilzomib) in relapsed or refractory multiple myeloma has completed enrollment with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib) (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Relapsed Refractory Multiple Myeloma | Phase 4 | Status: COMPLETED | Results posted: 2024-01-02